Centrexion acquires three analgesics from BI in deal worth up to $897mm
Executive Summary
Start-up Centrexion Therapeutics Corp. (chronic pain therapeutics) acquired three analgesics from Boehringer Ingelheim GMBH. The product acquisitions will strengthen Centrexion's existing pipeline (lead is currently CNTX4975; direct injection for pain) which is based on a patented exclusive injectable trans-capsaicin.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- Product Purchase
- R&D and Marketing (Licensing)
- Reverse Licensing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice